SURGICAL & CRITICAL CARE


alarming rate of deaths by testing women for HPV before it causes cancer. The BD Onclarity HPV Assay is the


only U.S. Food and Drug Administration (FDA) approved HPV test that individually identifies HPV 31, which poses a higher risk for cervical precancer as compared to HPV 18. The BD Onclarity HPV Assay with extended genotyping allows for a more precise, accurate way to measure a woman’s risk for developing cervical pre- cancer compared to an assay with partial genotyping. 3, 4, 5


compression artifacts and overlapping structures. These benefits will lead the way towards detecting more early-stage cancers - the point at which outcomes are much better for the patient.”


Enabling a more convenient setting for hysteroscopy


Up to one-third of women will experi- ence abnormal uterine bleeding in their lifetimes,9


which can be a sign of fibroids, polyps, endometriosis, adenomyosis, hyperplasia, infection, or cancer.10 Uterine cancer (also known as endome- trial cancer) is the most common gyneco- logic cancer in the U.S.11


a compact self-contained unit that com- bines all the components needed for hys- teroscopy—camera, light source, display, documentation, and network connectivity. Beyond state-of-the-art products, KARL


STORZ offers extensive value-added tools to facilitate seamless introduction of hys- teroscopy procedures to the office setting. These tools provide efficient management of assets, education of the staff, and finan- cial solutions to eliminate capital outlays. “At KARL STORZ, we are dedicated to the advancement of women’s health across the continuum of care,” Palian added.


and it is on the rise, The BD Onclarity HPV Assay


More accurate breast cancer diagnosis Early detection of breast cancer improves survival rates,6


but approximately 20-30%


of women with breast cancer have tumors that are missed by mammogram screening.7 The use of digital breast tomosynthesis (DBT), also known as 3D mammography, allows radiologists to look through tissue layers, “making it less likely they’ll miss an early sign of cancer.”8


Koning’s Breast CT (KBCT) is a revolu-


tionary 3D breast imaging device that pro- duces real 3D images of the breast. KBCT provides exceptional spatial resolution, dramatically improving the way clinicians visualize and evaluate breast tissue while improving the patient exam experience.


particularly among Black women. Recent research revealed the death rate from uter- ine cancer among Black women was twice that of other racial and ethnic groups.12 A new study points to a potential cause: hair straightening products. A study from the National Institutes of Health found women who use these products are twice as likely to develop uterine cancer than those who do not.13 Hysteroscopy is commonly used in the diagnosis of uterine cancer, as well as other conditions of the uterus, and KARL STORZ has developed technology and tools to facilitate this endoscopic technique outside of the hospital setting.


“Recent advances in endoscopic tech- nology are enabling a growing number of doctors to perform hysteroscopies in their offices rather than hospital-based set- tings,” said Anna Palian, Group Marketing Manager, Gynecology & Fetoscopy, KARL STORZ. “Moving hysteroscopy procedures out of the OR allows for increased physi- cian productivity and increased patient satisfaction while supporting population health in a cost-effective way.” KARL STORZ offers an extensive office


Koning Breast CT (KBCT) 3D breast imaging device


“Koning’s Breast CT technology was developed to address many of the limita- tions of modern mammography including eliminating painful breast compression and delivering a true 3-dimensional image data set of the breast at radiation dose lev- els in the same range as mammography,” said Naomi Cosman, Head of Marketing at Koning Corporation. “Through the adoption of this technology, patients will be more compliant, and physicians will have more detailed information free from


hysteroscopy portfolio, with products designed to perform the full range of endoscopic intrauterine procedures. A key enabling technology is the TELE PACK+,


Technologies now shaping pregnancy, birth, neonatal care Hospitals have made major strides in maternal/fetal care over the decades to improve outcomes, reduce the risk for complications, and improve patient comfort and satisfaction. Research has shown how “ensuring maternal satisfac- tion of childbirth services is essential for preventing anxiety, promoting treatment adherence, preventing disease and health promotion.”14


In the neonatal intensive care unit (NICU), family involvement in their baby’s care can improve both short- and long-term outcomes, help facilitate successful breast- feeding, and promote healthy growth and neurodevelopment.15


Here are some ways technology is sup-


porting higher satisfaction, improved qual- ity, and healthier patients from prenatal through postnatal care.


Monitoring fetal development Ultrasound is a critical tool for monitor- ing the health of mom and baby during pregnancy, but there are multiple limita- tions on data sharing of images between providers and their patients, says Matthijs Groot Wassink, General Manager, Point of Care Ultrasound at Philips. When an ultrasound is performed by one provider in a healthcare facility, it is challenging for them to share it with providers at other facilities for collaborative decision making.


If a provider wants to share KARL STORZ office hysteroscopy equipment 18 December 2022 • HEALTHCARE PURCHASING NEWS • hpnonline.com


ultrasound images with their patient, they can use costly thermal printing or down- load the information onto a USB drive or DVD, both of which present the risk that the images or data will be misplaced. For patients who want real-time data on their


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54